Argentinean crackdown on pharma imports causes problems for industry
This article was originally published in SRA
Executive Summary
Protectionist measures aimed at improving Argentina's trade balance are causing problems for both local and multinational pharmaceutical companies operating in the country. Nevertheless, talks between the government and industry are ongoing and the ministry for industry has hinted that import restrictions may be eased in certain circumstances.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.